News & Presse

Gemeinnützige Vereine gesucht

Leverkusen, Juli 2020 – Bereits zum siebten Mal ruft der Arzneimittelimporteur Orifarm seine Geschäftspartner zur Teilnahme an der „Aktion Teilkraft“ auf. Mit der Charity-Initiative unterstützt das Unternehmen seit 2014 karitative Einrichtungen in ganz Deutschland. Auch 2020 stellt Orifarm wieder einen fünfstelligen Eurobetrag in den Dienst der guten Sache.

15.000 € an Fördergeldern lobt das Unternehmen allein 2020 im Rahmen der „Aktion Teilkraft“ aus – und seitdem Orifarm die Charity-Initiative 2014 ins Leben gerufen hat, ist bereits mehr als das Zehnfache dieser Summe geflossen. So beeindruckend die Höhe der finanziellen Zuwendung ist, so groß ist auch die Bandbreite der bislang unterstützten Einrichtungen in ganz Deutschland. Sie reicht vom Verein für Trauerbegleitung über die Einrichtung für Obdachlose und die Selbsthilfegruppe von an Amyotropher Lateralsklerose (ALS) erkrankten Menschen bis zum Kinderhospiz. Zuletzt konnte Orifarm unter anderem den Aufbau einer Schule für Therapiehunde unterstützen.

Unterstützung für unterschiedlichste Einrichtungen

In Zeiten, wie wir sie gerade erleben, ist es umso wichtiger, dass Unternehmen sich zu ihrer sozialen Verantwortung bekennen. Daher ruft Orifarm auch in diesem Sommer wieder Apotheken und Großhandelspartner dazu auf, Vorschläge für die „Aktion Teilkraft“ einzureichen. Gesucht sind Vereine mit medizinisch-sozialem Hintergrund und nachgewiesener Gemeinnützigkeit, die sich z. B. für Kinder und Ältere, Kranke oder Menschen mit Behinderung einsetzen. Nach Abschluss der Bewerbungsphase, die vom 1. August bis 30. September 2020 andauert, werden unter allen qualifizierten Einreichungen drei Förderpreise verlost. Die Gewinner können sich über Zuwendungen in Höhe von 2.500 €, 5.000 € oder sogar 7.500 € freuen.

Alle Informationen finden Interessierte unter der Adresse www.orifarm.de/aktion-teilkraft.

Die Orifarm Group („Orifarm“), eines der führenden Pharmaunternehmen der Nordregion, hat eine Vereinbarung zur Übernahme eines Portfolios ausgewählter rezeptfreier und verschreibungspflichtiger Arzneimittelprodukte, die in Europa von Takeda Pharmaceutical Company Limited („Takeda“) verkauft werden, zum Preis von bis zu 615 Millionen € unterzeichnet. Die Orifarm Group hat die Rechte an ca. 110 Arzneimitteln sowie zwei Produktionsstätten erworben.

Pressemitteilung

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

In 2019, the turnover of the Orifarm Group reached MEUR 982. An 18% increase compared to the record-breaking year 2018. Profit before tax in 2019 reached MEUR 45.4 corresponding to a rise of 30% compared to the previous record from the financial year 2018.

The progress in 2019 is mainly attributable to a strong sales growth of parallel imported pharmaceuticals at the German market, which is also Orifarm’s largest market. Orifarm increased its market share and generated both higher turnover and earnings. Also generic pharmaceuticals showed progress where in particular the Norwegian market grew.

For Orifarm’s CEO Erik Sandberg the result is more than approved.

- We have all worked hard and been careful not to rest on the laurels from last year’s result, and I am proud of the result we have achieved as a team. In addition to the awesome result we have also implemented a number of digitalization projects in our operation, which will make us even more competitive in the future. A future, of which we have high hopes. 

Targets of continued growth

Orifarm Group has ambitions to continue the growth in the next few years. There is still a lot of potential within the two existing business areas, parallel imported pharmaceuticals and sale of generic pharmaceuticals. All in all, Orifarm has sold more than 26 million boxes of medicine in 2019. This entails another record for Orifarm.

In 2019, operating income increased by MEUR 7.8 to MEUR 48.1.

The parallel import business has not only increased the turnover in Germany, but also in Finland, Austria, and United Kingdom. However, the exchange rates in especially United Kingdom and Sweden have affected the earnings unfavorable.

The sale of generic pharmaceuticals in the Nordic countries has also been in clear progress in 2019, where turnover has increased with nearly 8%. 

Acquisition – a part of the growth strategy

Contemporary with the growth of the present business, Orifarm Group acquired the London based company Pilatus Comparator Solutions during summer 2019. Pilatus adds new business areas like comparator sourcing and unlicensed medicines to Orifarm Group.

- The acquisition of Pilatus is an example of the fact, that we keep a close eye on possible acquisitions which have synergies in terms of our present business areas. Pilatus has added some new activities, which we are about to develop and which we can infuse with a lot of muscle work with our comprehensive experience in parallel import, says Orifarm’s CEO Erik Sandberg. 

Outlook for 2020

Orifarm Group’s target is a minor growth in revenue in 2020 and retention of earnings at 2019 level. 

For further information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351
CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121 

Key ratio – Orifarm Group (in MEUR)

Facts about Orifarm Group
Orifarm Group is the largest supplier of parallel imported pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group is engaged in parallel import of medicines from the EU/EEA which are sold to Denmark, Norway, Sweden, Finland, Germany, The Netherlands, Austria, United Kingdom, and Belgium.

In addition to this, the Group is engaged in the sale of generic pharmaceuticals in the Nordic countries. A generic pharmaceuticals contain the same effects as the original pharmaceutical. However, the effect is no longer subject to patent and therefore the generic pharmaceutical can be produced and marketed at a lower price than the corresponding original pharmaceutical.

Orifarm Group has its headquarters in Odense and the entire Group employs close to 1,200 people today, of which around 360 in Odense.

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

In 2019, the turnover of the Orifarm Group reached MEUR 982. An 18% increase compared to the record-breaking year 2018. Profit before tax in 2019 reached MEUR 45.4 corresponding to a rise of 30% compared to the previous record from the financial year 2018.

The progress in 2019 is mainly attributable to a strong sales growth of parallel imported pharmaceuticals at the German market, which is also Orifarm’s largest market. Orifarm increased its market share and generated both higher turnover and earnings. Also generic pharmaceuticals showed progress where in particular the Norwegian market grew.

For Orifarm’s CEO Erik Sandberg the result is more than approved.

- We have all worked hard and been careful not to rest on the laurels from last year’s result, and I am proud of the result we have achieved as a team. In addition to the awesome result we have also implemented a number of digitalization projects in our operation, which will make us even more competitive in the future. A future, of which we have high hopes. 

Targets of continued growth

Orifarm Group has ambitions to continue the growth in the next few years. There is still a lot of potential within the two existing business areas, parallel imported pharmaceuticals and sale of generic pharmaceuticals. All in all, Orifarm has sold more than 26 million boxes of medicine in 2019. This entails another record for Orifarm.

In 2019, operating income increased by MEUR 7.8 to MEUR 48.1.

The parallel import business has not only increased the turnover in Germany, but also in Finland, Austria, and United Kingdom. However, the exchange rates in especially United Kingdom and Sweden have affected the earnings unfavorable.

The sale of generic pharmaceuticals in the Nordic countries has also been in clear progress in 2019, where turnover has increased with nearly 8%. 

Acquisition – a part of the growth strategy

Contemporary with the growth of the present business, Orifarm Group acquired the London based company Pilatus Comparator Solutions during summer 2019. Pilatus adds new business areas like comparator sourcing and unlicensed medicines to Orifarm Group.

- The acquisition of Pilatus is an example of the fact, that we keep a close eye on possible acquisitions which have synergies in terms of our present business areas. Pilatus has added some new activities, which we are about to develop and which we can infuse with a lot of muscle work with our comprehensive experience in parallel import, says Orifarm’s CEO Erik Sandberg. 

Outlook for 2020

Orifarm Group’s target is a minor growth in revenue in 2020 and retention of earnings at 2019 level. 

For further information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351
CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121 

Key ratio – Orifarm Group (in MEUR)

Facts about Orifarm Group
Orifarm Group is the largest supplier of parallel imported pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group is engaged in parallel import of medicines from the EU/EEA which are sold to Denmark, Norway, Sweden, Finland, Germany, The Netherlands, Austria, United Kingdom, and Belgium.

In addition to this, the Group is engaged in the sale of generic pharmaceuticals in the Nordic countries. A generic pharmaceuticals contain the same effects as the original pharmaceutical. However, the effect is no longer subject to patent and therefore the generic pharmaceutical can be produced and marketed at a lower price than the corresponding original pharmaceutical.

Orifarm Group has its headquarters in Odense and the entire Group employs close to 1,200 people today, of which around 360 in Odense.

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.

In 2019, the turnover of the Orifarm Group reached MEUR 982. An 18% increase compared to the record-breaking year 2018. Profit before tax in 2019 reached MEUR 45.4 corresponding to a rise of 30% compared to the previous record from the financial year 2018.

The progress in 2019 is mainly attributable to a strong sales growth of parallel imported pharmaceuticals at the German market, which is also Orifarm’s largest market. Orifarm increased its market share and generated both higher turnover and earnings. Also generic pharmaceuticals showed progress where in particular the Norwegian market grew.

For Orifarm’s CEO Erik Sandberg the result is more than approved.

- We have all worked hard and been careful not to rest on the laurels from last year’s result, and I am proud of the result we have achieved as a team. In addition to the awesome result we have also implemented a number of digitalization projects in our operation, which will make us even more competitive in the future. A future, of which we have high hopes. 

Targets of continued growth

Orifarm Group has ambitions to continue the growth in the next few years. There is still a lot of potential within the two existing business areas, parallel imported pharmaceuticals and sale of generic pharmaceuticals. All in all, Orifarm has sold more than 26 million boxes of medicine in 2019. This entails another record for Orifarm.

In 2019, operating income increased by MEUR 7.8 to MEUR 48.1.

The parallel import business has not only increased the turnover in Germany, but also in Finland, Austria, and United Kingdom. However, the exchange rates in especially United Kingdom and Sweden have affected the earnings unfavorable.

The sale of generic pharmaceuticals in the Nordic countries has also been in clear progress in 2019, where turnover has increased with nearly 8%. 

Acquisition – a part of the growth strategy

Contemporary with the growth of the present business, Orifarm Group acquired the London based company Pilatus Comparator Solutions during summer 2019. Pilatus adds new business areas like comparator sourcing and unlicensed medicines to Orifarm Group.

- The acquisition of Pilatus is an example of the fact, that we keep a close eye on possible acquisitions which have synergies in terms of our present business areas. Pilatus has added some new activities, which we are about to develop and which we can infuse with a lot of muscle work with our comprehensive experience in parallel import, says Orifarm’s CEO Erik Sandberg. 

Outlook for 2020

Orifarm Group’s target is a minor growth in revenue in 2020 and retention of earnings at 2019 level. 

For further information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351
CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121 

Key ratio – Orifarm Group (in MEUR)

Facts about Orifarm Group
Orifarm Group is the largest supplier of parallel imported pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group is engaged in parallel import of medicines from the EU/EEA which are sold to Denmark, Norway, Sweden, Finland, Germany, The Netherlands, Austria, United Kingdom, and Belgium.

In addition to this, the Group is engaged in the sale of generic pharmaceuticals in the Nordic countries. A generic pharmaceuticals contain the same effects as the original pharmaceutical. However, the effect is no longer subject to patent and therefore the generic pharmaceutical can be produced and marketed at a lower price than the corresponding original pharmaceutical.

Orifarm Group has its headquarters in Odense and the entire Group employs close to 1,200 people today, of which around 360 in Odense.

Charity-Initiative „Aktion Teilkraft“ von Orifarm

Leverkusen, September 2019. Mit der Charity-Initiative „Aktion Teilkraft“ unterstützt der Leverkusener Importarzneimittel-Spezialist Orifarm ausgewählte gemeinnützige Einrichtungen – in diesem Jahr bereits zum sechsten Mal und erneut mit Fördergeldern in einer Gesamthöhe von mehr als 20.000 €.

Der Aufruf zur Teilnahme kam per Flyer mit Herz 

Orifarm-Geschäftspartner in ganz Deutschland haben im Frühsommer dieses Jahres eine auffällig gestaltete Sendung in der Post gefunden. Mit dem vierseitigen Flyer in Herzform hat Orifarm einerseits Apotheken-Teams in ganz Deutschland zur Teilnahme an seinem traditionell im Sommer veranstalteten Gewinnspiel eingeladen. Damit verbunden war ein zweiter Aufruf: Auch 2019 hat Orifarm die Adressaten gebeten, ihre persönlichen Favoriten für die Charity-Initiative „Aktion Teilkraft“ zu nominieren.

Unterstützung für unterschiedlichste Einrichtungen

Ins Leben gerufen hat der Arzneimittel-Importeur die Initiative im Jahr 2014, seitdem hat Orifarm Vereine mit medizinisch-sozialem Hintergrund in Regionen in ganz Deutschland unterstützt – vom Projekt für Obdachlose in Ludwigshafen über die Interessenvertretung für behinderte Menschen in Weimar bis zum Hamburger Verein, der sich für Menschen mit Neurofibromatose stark macht. Insgesamt hat Orifarm in den vergangenen fünf Jahren Fördergelder in Höhe von mehr als 150.000 € für ganz unterschiedliche Zwecke bereitgestellt. Grundsätzlich kommen alle eingetragenen Institutionen, Vereine und Organisationen mit nachgewiesener Gemeinnützigkeit in Frage, die sinnvolle und förderwürdige Angebote für Kinder und Ältere, Kranke oder Menschen mit Behinderung bereitstellen. Für die Nominierungsphase setzt das Unternehmen traditionell auf die Mithilfe seiner Geschäftspartner – das war auch 2019 so.

Die Sieger für 2019 stehen fest

In der Zeit zwischen dem 01. Juli und dem 15. September konnten Apotheken und Großhandelspartner Einrichtungen benennen, welche die Voraussetzungen für eine Förderung erfüllen. Alternativ konnten diese sich über ein unter der Web-Adresse  www.orifarm.de/aktion-teilkraft bereitgestelltes Online-Formular auch selbst bewerben. Mittlerweile ist der Auswahlprozess abgeschlossen, die Gewinner der Förderpreise für 2019 stehen fest. Über eine Zuwendung in Höhe von 5.000 € darf sich der Verein AIDS-AUFKLÄRUNG e.V. freuen. Unterstützung in Höhe von 7.500 € erhält das Kinder-Hospiz Sternenbrücke in Hamburg. Den mit 10.000 € höchstdotierten Förderpreis erhält in diesem Jahr die Organisation Tröstende Pfoten Therapiehunde für Deutschland e.V.. Dieser Verein organisiert und finanziert Einsätze von Therapiebegleithundeteams für eine tiergestützte Therapie bei schwerkranken Menschen und deren Familien. Mit dem Fördergeld soll der Aufbau einer eigenen Hundeschule unterstützt werden. Alle Einrichtungen wurden inzwischen benachrichtigt.

Über Orifarm

Die Orifarm GmbH mit Sitz in Leverkusen ist Teil der 1994 gegründeten dänischen Orifarm-Gruppe, Europas führendem Arzneimittelimporteur. Derzeit beschäftigt das auf den Import von Original-Arzneimitteln spezialisierte Unternehmen rund 140 Mitarbeiterinnen und Mitarbeiter am Standort Leverkusen. Das Produktportfolio der Orifarm GmbH umfasst derzeit mehr als 1.300 Präparate, darunter Rx- und OTC-Präparate sowie Diagnostika und Betäubungsmittel. Eines der erklärten Ziele des Unternehmens lautet, effektiv zur Senkung des Kostendrucks auf die Gesundheitssysteme beizutragen; Patientensicherheit und Kundenzufriedenheit stehen dabei im Mittelpunkt. Dem Anspruch auf die Übernahme sozialer Verantwortung gerecht wird das Unternehmen durch die Unterstützung unterschiedlichster gemeinnütziger Projekte im In- und Ausland.

Orifarm-Gewinnspiel „Herzmomente“

Leverkusen, September 2019. Im Frühsommer 2019 hatte Importarzneimittel-Spezialist Orifarm Apotheken-Teams in ganz Deutschland erneut zur Teilnahme an seinem traditionellen Sommer-Gewinnspiel eingeladen. Inzwischen stehen die Sieger der drei Gewinne fest.     

Sommer-Gewinnspiel für Apotheken 

Für viele Apotheken-Teams dürfte es inzwischen Tradition sein: das alljährliche Sommer-Gewinnspiel von Orifarm. Auch in diesem Jahr hat das Unternehmen zur Teilnahme eingeladen – und das herzlicher denn je: Nachdem in den Vorjahren Deutschlands coolste PTA gesucht waren, standen 2019 die persönlichen „Herzmomente“ im Mittelpunkt. „Zeig uns, wofür dein Herz schlägt und was dich glücklich macht“, lautete die Botschaft des herzförmigen Flyers, den Apotheken-Teams deutschlandweit im Mai in der Post fanden. Getreu dem Gewinnspiel-Motto „Herzmomente“ durften Herzen in den Schnappschüssen ausdrücklich eine Rolle spielen. Das haben sich die teilnehmenden Teams nicht zweimal sagen lassen, und auch in diesem Jahr durfte Orifarm sich wieder über rege Beteiligung und zahlreiche originelle Einsendungen freuen. Mittlerweile stehen die Sieger fest.

Gewinner mit Herz

Ganz oben auf dem Siegertreppchen gelandet ist das Team der Apotheke im Pep in Grimma. Für ihr tolles Gruppenfoto mit Herz dürfen sie sich über einen Teamabend im Wert von 350 € freuen. Knapp dahinter auf dem zweiten Platz: das Team der Stresemann Apotheke in Hamburg. Als Lohn für ihr herziges Bild winkt ein Smoothie Maker inklusive Obst-Abo. Und auch die Einsendung der Hasenleiser Apotheke in Heidelberg erobert jedes Herz im Sturm: Für ihr sommerliches Gruppenfoto dürfen sich die Teammitglieder über den dritten Platz und einen lecker gefüllten Picknick-Korb freuen.

Alle Einsendungen sind auch online 

Möchten Sie wissen, mit welchen kreativen Beiträgen die teilnehmenden Teams außerdem überrascht haben? Viele Einsendungen präsentiert Orifarm in diesen Tagen auf seiner Facebook-Seite unter der Adresse https://www.facebook.com/orifarmdeutschland/. Das Unternehmen dankt noch einmal allen Teams herzlich für die rege Beteiligung und die Vielzahl toller Einsendungen. Und verspricht schon heute allen, die diesmal nicht unter den glücklichen Gewinnern waren: Im Sommer 2020 winkt ganz bestimmt eine neue Chance.    

Leverkusen, Juni 2019 – Mit der „Aktion Teilkraft“ unterstützt Importarzneimittel-Spezialist Orifarm bereits seit 2014 ausgewählte karitative Einrichtungen in ganz Deutschland. Auch 2019 stellt das Unternehmen mit Sitz in Leverkusen dafür Fördergelder in einer Gesamthöhe von mehr als 20.000 € zur Verfügung. In diesem Jahr bündelt Orifarm die Aktion mit einem Gewinnspiel für Apotheken-Teams, das der Importeur traditionell während der Sommermonate auslobt.      

Preise fürs Apotheken-Team

Viele Apotheken-Teams in ganz Deutschland erhalten bald „herzliche“ Neuigkeiten von Orifarm: Der Arzneimittelimporteur ruft zur Teilnahme an zwei Aktionen auf, die unter dem gemeinsamen Motto „Herzmomente“ stehen.

Die Aufforderung, Herz zu zeigen, dürfen Adressaten dabei durchaus wörtlich verstehen. Bei dem von Orifarm traditionell im Sommer veranstalteten Gewinnspiel für Apotheken-Mitarbeiter gilt es in diesem Jahr glückliche Augenblicke auf einem Foto festzuhalten – Herzen dürfen dabei in den Schnappschüssen ausdrücklich eine Rolle spielen. Wer seinen persönlichen „Herzmoment des Sommers“ gelungen in Szene setzt, darf sich mit etwas Glück über einen von drei attraktiven Preisen fürs ganze Team freuen: Verlost werden ein lecker gefüllter Picknickkorb sowie ein Smoothie-Maker inklusive Obst-Abo und als Hauptgewinn winkt ein sommerlicher Teamabend im Wert von 350 €. Teilnahmebedingungen und weitere Informationen zum Gewinnspiel finden Sie auf unserem Orifarm Blog. 

Zusammen mit dem Gewinnspiel werden die Apotheken außerdem dazu aufgerufen Herz für andere zu zeigen und Vorschläge für die Orifarm Charity-Initiative „Aktion Teilkraft“ einzureichen: Vereine mit medizinisch-sozialem Hintergrund, die sich mit Herzblut für eine gute Sache einsetzen.

Mitmachen für den guten Zweck

Orifarm veranstaltet diese wohltätige Aktion bereits zum sechsten Mal und hat in der Vergangenheit ganz unterschiedliche Organisationen mit insgesamt mehr als 150.000 € unterstützt. Die Bandbreite der Einrichtungen, die für die Spendensummen in Frage kommen, ist enorm. In den letzten Jahren wurden unter anderem ein Projekt für Obdachlose sowie ein Radiosender unterstützt, der über die Gefahren von Depressionserkrankungen aufklärt. Im vergangenen Jahr ging der Hauptpreis an die Ronald-McDonald-Oase der Erlanger Kinderklinik.

Eines haben viele dieser Einrichtungen jedoch gemeinsam: Dass sie für die Vergabe der Förderpreise in Höhe von 5.000 €, 7.500 € und 10.000 € vorgeschlagen wurden, verdanken sie in der Regel Apotheken sowie Großhandelspartnern von Orifarm – denn für die Nominierung setzt der Arzneimittelimporteur immer wieder ausdrücklich auf die Unterstützung seiner Geschäftspartner.

Alternativ können sich gemeinnützige Organisationen und andere Einrichtungen, welche die Voraussetzungen zur Teilnahme erfüllen, aber auch selbst bewerben. Wer mehr wissen möchte, findet unter www.orifarm.de/aktion-teilkraft alle Informationen.

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings.

This week, Orifarm Group releases its 2018 Annual Report and the result beats all former company records. The Group's revenue increased by 4.7 % in 2018 to MEUR 833. Operating income excl. non-recurring items increased by MEUR 6.5 to MEUR 40.3, and earnings before tax increased to  record high MEUR 34.9. A very satisfactory result for the Group, which also exceeds the expectations.

Erik Sandberg, who officially took over as CEO in January 2019, says:

“In many ways, 2018 has been a fantastic year for us. A year where we have met lots of challenges in the markets, and where we have been through a major reorganization internally. Nevertheless, we have succeeded in creating great results for the Group together. It proves our willingness and ability to make a difference - for consumers, society and the company. All employees can be proud of what we achieved together in 2018, as it would not have happened without them.”

More consumers have bought Orifarm's products

The Group's financial growth was especially generated in the parallel import business, which repackages and sells pharmaceutical products within the EU / EEA. The parallel import business sold 11 % more products in 2018 compared to 2017, which led to growth in both revenue and earnings in 2018.

The 2018 revenue from parallel imported products totalled MEUR 756. This is an increase of 4.9 % compared to 2017. The result of main activities excl. non-recurring items increased by MEUR 8.0 to MEUR 34.2.

In spite of intense competition in 2018, Orifarm succeeded in generating great results in Germany, which is the Group's largest market, as well as in Denmark, the Netherlands and Austria.

In Sweden, the Group's earnings has been under pressure due to the Swedish currency exchange rate, but Orifarm maintained its position at the Swedish market. The parallel import business sold more products in the UK in 2018 compared to the previous year, but the weak British currency puts pressure on the profit.

The Group's other business area, the generic pharmaceuticals, had a difficult year with stagnation in revenue and decreasing income. Nevertheless, the generic pharmaceuticals sold 4 % more products in 2018 compared to the year before.

Challenging market conditions and challenges in maintaining a stable supply of few, and normally well performing products, put pressure on the Group's revenue and earnings from the generic products.

Operating income fell by MEUR 2.6 to MEUR 9.7, however, it was possible to maintain revenue at the same level as in 2017 (MEUR 9.7).

“We have done well in 2018 in difficult conditions, and we have the ambition and the belief in being able to continue growth and a positive development for Orifarm. But we are also realistic and 2019 will be at least as challenging as 2018, characterized by strong competition at all Orifarm's markets. But we have so many skilled employees who drive Orifarm forward. Therefore, I am confident that together we can meet the common goals for 2019,” says Erik Sandberg, CEO at Orifarm Group.

Expectations for 2019

For 2019, Orifarm Group has a target of revenue growth in the range of 3-6 % and an operating income at 2018 level. 

For more information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351

CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121

Key figures, Orifarm Group (in MEUR)

Facts about Orifarm Group

Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in import, production, re-packaging, distribution, registration and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria and the United Kingdom.

Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordics. A generic product contains the same active ingredients as the original product. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the original.

The Orifarm Group headquarters are in Odense, Denmark. The Group employs approximately 1.200 people.

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings.

This week, Orifarm Group releases its 2018 Annual Report and the result beats all former company records. The Group's revenue increased by 4.7 % in 2018 to MEUR 833. Operating income excl. non-recurring items increased by MEUR 6.5 to MEUR 40.3, and earnings before tax increased to  record high MEUR 34.9. A very satisfactory result for the Group, which also exceeds the expectations.

Erik Sandberg, who officially took over as CEO in January 2019, says:

“In many ways, 2018 has been a fantastic year for us. A year where we have met lots of challenges in the markets, and where we have been through a major reorganization internally. Nevertheless, we have succeeded in creating great results for the Group together. It proves our willingness and ability to make a difference - for consumers, society and the company. All employees can be proud of what we achieved together in 2018, as it would not have happened without them.”

More consumers have bought Orifarm's products

The Group's financial growth was especially generated in the parallel import business, which repackages and sells pharmaceutical products within the EU / EEA. The parallel import business sold 11 % more products in 2018 compared to 2017, which led to growth in both revenue and earnings in 2018.

The 2018 revenue from parallel imported products totalled MEUR 756. This is an increase of 4.9 % compared to 2017. The result of main activities excl. non-recurring items increased by MEUR 8.0 to MEUR 34.2.

In spite of intense competition in 2018, Orifarm succeeded in generating great results in Germany, which is the Group's largest market, as well as in Denmark, the Netherlands and Austria.

In Sweden, the Group's earnings has been under pressure due to the Swedish currency exchange rate, but Orifarm maintained its position at the Swedish market. The parallel import business sold more products in the UK in 2018 compared to the previous year, but the weak British currency puts pressure on the profit.

The Group's other business area, the generic pharmaceuticals, had a difficult year with stagnation in revenue and decreasing income. Nevertheless, the generic pharmaceuticals sold 4 % more products in 2018 compared to the year before.

Challenging market conditions and challenges in maintaining a stable supply of few, and normally well performing products, put pressure on the Group's revenue and earnings from the generic products.

Operating income fell by MEUR 2.6 to MEUR 9.7, however, it was possible to maintain revenue at the same level as in 2017 (MEUR 9.7).

“We have done well in 2018 in difficult conditions, and we have the ambition and the belief in being able to continue growth and a positive development for Orifarm. But we are also realistic and 2019 will be at least as challenging as 2018, characterized by strong competition at all Orifarm's markets. But we have so many skilled employees who drive Orifarm forward. Therefore, I am confident that together we can meet the common goals for 2019,” says Erik Sandberg, CEO at Orifarm Group.

Expectations for 2019

For 2019, Orifarm Group has a target of revenue growth in the range of 3-6 % and an operating income at 2018 level. 

For more information, please contact:

Communication Manager, Andreas Lykke Sognstrup, tel. +45 3012 2351

CEO, Orifarm Group A/S, Erik Sandberg, tel. +45 2265 0121

Key figures, Orifarm Group (in MEUR)

Facts about Orifarm Group

Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and one of the largest suppliers of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in import, production, re-packaging, distribution, registration and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria and the United Kingdom.

Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordics. A generic product contains the same active ingredients as the original product. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the original.

The Orifarm Group headquarters are in Odense, Denmark. The Group employs approximately 1.200 people.